张小楠, 李占强, 芦殿香. 基于肺血管细胞增殖抑制的肺动脉高压治疗药物J. 药学学报, 2022,57(3): 557-567. doi: 10.16438/j.0513-4870.2021-1126
引用本文: 张小楠, 李占强, 芦殿香. 基于肺血管细胞增殖抑制的肺动脉高压治疗药物J. 药学学报, 2022,57(3): 557-567. doi: 10.16438/j.0513-4870.2021-1126
ZHANG Xiao-nan, LI Zhan-qiang, LU Dian-xiang. Treatment of pulmonary hypertension based on inhibition of pulmonary vascular cell proliferationJ. Acta Pharmaceutica Sinica, 2022,57(3): 557-567. doi: 10.16438/j.0513-4870.2021-1126
Citation: ZHANG Xiao-nan, LI Zhan-qiang, LU Dian-xiang. Treatment of pulmonary hypertension based on inhibition of pulmonary vascular cell proliferationJ. Acta Pharmaceutica Sinica, 2022,57(3): 557-567. doi: 10.16438/j.0513-4870.2021-1126

基于肺血管细胞增殖抑制的肺动脉高压治疗药物

Treatment of pulmonary hypertension based on inhibition of pulmonary vascular cell proliferation

  • 摘要: 肺动脉高压(pulmonary hypertension,PH)是一种进展迅速的肺血管疾病,预后不良,最终导致右心衰竭和死亡。肺小动脉的重塑是PH的重要病理特征。位于肺动脉中层的肺动脉平滑肌细胞(pulmonary arterial smooth muscle cells,PASMCs)表现出类似于肿瘤细胞的异常增殖和抗凋亡特征,是肺血管重塑的主要启动因素。本文主要讨论在PASMCs增殖中起关键作用的信号通路以及对细胞增殖通路为靶点的抑制剂的最新研究进展做一综述,以期为PH的靶向治疗提供新的视角。

     

    Abstract: Pulmonary hypertension is a rapidly progressing disease of the lung vasculature with poor prognosis, ultimately leading to right heart failure and death. The remodeling of small pulmonary arteries represents an important pathological characteristic of pulmonary hypertension. Pulmonary arterial smooth muscle cells (PASMCs) located in the middle layer of pulmonary artery exhibit hyperproliferation and resistance to apoptosis, which is the main initiator of pulmonary vascular remodeling and similar to that seen in tumor cells. In this review we focus on the signaling pathways that play a key role in PASMCs proliferation and the latest research progress on inhibitors targeting cell proliferation pathways to provide a new perspective for the treatment of PH.

     

/

返回文章
返回